Tagged with access

USA Market access and pricing expert Barbara Jaszewski outlines the issues inherent in the USA importing drugs from Canada and why such proposals retain political capital despite massive and proven flaws.   Drug importation is a curious “zombie” proposal that never seems to die Donald Trump and Bernie Sanders have one…

USA Stephen J. Ubl, president and CEO of PhRMA, outlines the unprecedented collaboration and speed with which the biopharmaceutical industry has responded to the COVID-19 pandemic and the solutions that PhRMA is proposing to lower patient costs while protecting innovation and access.   We know that our innovation and our collaboration…

USA Zogenix’s Dr Stephen Farr shares his remarkable career journey from academia to industry, the company’s transition from pain therapeutics into rare diseases, product launch strategies, access and affordability issues, and talent attraction challenges.   While it is true you can make great contributions in academia, I think you can make…

Switzerland In a wide-ranging interview, Henrik Asmussen outlines his priorities for Amgen’s important Swiss affiliate, market access and pricing challenges, the company’s exciting pipeline, and what makes Amgen Switzerland a great place to work.   I was told when I came that Switzerland is a safe haven with easy access. What…

USA Takeda USA’s Ramona Sequeira outlines her expanded role as president of global portfolio commercialization, the crucial importance of investing in culture, and the company’s multifaceted response to the COVID-19 crisis.   In general, through the global COVID response, we’ve seen the walls between companies and across sectors come down as…

USA Brad Campbell, president and COO of US rare disease specialist Amicus, talks domestic and global product launches, the company’s first steps into the gene therapy space, and how a biotech success story like Amicus can be a guiding light in market access and pricing discussions.   Ultimately, we envision our…

USA Tatsuya Kaihara, head of US operations for Japanese eyecare specialist Santen, describes his excitement at bringing two new ophthalmic advancements to the US market, the similarities, differences, and synergies of Japanese and American innovation, and the challenges of building a unified corporate culture.   This is a very exciting moment…

Switzerland Biogen Switzerland’s Dr Katharina Gasser outlines how the company’s 100 percent commitment to neuroscience helps it to stand apart, why Switzerland will continue to play a vital role in Biogen’s global clinical research footprint, and some of the country’s market access and pricing challenges. Dr Gasser also highlights Biogen’s burgeoning…

Switzerland Urs Vögeli, managing director for Janssen Switzerland, outlines the importance of the Swiss operations to Janssen, his interesting career journey, Janssen’s commitment to bringing transformational medical innovations to Swiss patients, as well as his perspectives on talent development within the industry.   Switzerland is very open to innovative products, and…

Switzerland Switzerland, rightly regarded as one of the world’s most innovative nations, risks damaging its reputation if innovative new medicines continue to face significant delays and roadblocks in their introduction to the domestic Swiss market. Key stakeholders from pharma industry associations Interpharma and scienceindustries and local affiliate heads for multinationals Bayer…

Norway Karita Bekkemellem of Norwegian pharma association LMI highlights her work building up the profile of the industry in Norway, the market access and pricing challenges facing her member companies, and the country’s enduring potential as a leading clinical trial destination.   Through diligent and long-term thinking, and building bridges and…

Switzerland Axel Steiger, CEO and CFO for Bayer Switzerland, outlines the importance of the Swiss operations as one of the key global hubs for Bayer, his leadership and talent management philosophy, the investment and commitment Bayer is making towards becoming a global oncology player, as well as his perspectives on digital…